Mounjaro vs Foundayo

Mounjaro (tirzepatide) and Foundayo (orforglipron) are both manufactured by Eli Lilly, but they are different molecules, different classes, and approved for different uses. Mounjaro is a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes. Foundayo is an oral small-molecule GLP-1 receptor agonist approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. The weight-management equivalent of Mounjaro is Zepbound, which is the same active ingredient (tirzepatide) with the obesity label.

FDA-Approved Indications

According to the Mounjaro prescribing information, tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Chronic weight management is not a labeled Mounjaro indication, although Zepbound (tirzepatide) is FDA-approved for weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Foundayo is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. Type 2 diabetes is not currently on the Foundayo label, although Eli Lilly has reported positive Phase 3 results from the ACHIEVE program studying orforglipron in diabetes.

Different Mechanisms

Tirzepatide binds and activates two incretin receptors: GIP and GLP-1. Activating both is hypothesized to contribute to the larger weight losses observed in tirzepatide trials compared with selective GLP-1 agonists, though head-to-head trial data confirms superiority in obesity rather than any specific mechanistic claim.

Orforglipron binds only the GLP-1 receptor and is notable for being a small molecule rather than a peptide. This allows the drug to be taken orally without the strict water-and-fasting rules required for peptide-based oral semaglutide (Rybelsus), and with or without food.

Route of Administration

Mounjaro is a once-weekly subcutaneous injection, delivered with a prefilled pen.

Foundayo is a once-daily oral tablet that can be taken at any time of day, with or without food or water.

For patients who want to avoid injections entirely, Foundayo is the first oral GLP-1 without food restrictions. Mounjaro does not have an oral alternative at this time; patients seeking oral options who specifically want tirzepatide's dual-agonist mechanism do not currently have that choice.

Weight Loss and Efficacy Data

Mounjaro has been studied in people with type 2 diabetes in the SURPASS program, where it reduced A1C and body weight, with weight reductions varying by dose and baseline characteristics. The tirzepatide obesity program was conducted under the Zepbound label; in SURMOUNT-1, tirzepatide 15 mg produced approximately 22.5% body weight reduction over 72 weeks in adults with obesity and without diabetes.

In ATTAIN-1 (72 weeks, adults with obesity or overweight plus a comorbidity, no diabetes), orforglipron 36 mg produced approximately 12.4% body weight reduction versus about 0.9% with placebo. Approximately 59.6% of participants on the highest dose achieved at least 10% body weight loss and 39.6% achieved at least 15%.

Caveats: these are different trials with different patient populations, so direct cross-trial comparison overestimates or underestimates the difference depending on covariates. The fair comparison for an obesity indication is Zepbound vs Foundayo rather than Mounjaro vs Foundayo. For patients with type 2 diabetes, neither Mounjaro's glycemic data nor Foundayo's weight data is directly transferable, and prescribing should rest on the FDA label.

Dosing Schedules

Mounjaro is titrated starting at 2.5 mg weekly for 4 weeks (a starter dose, not therapeutic), then increased to 5 mg weekly. Additional increases to 7.5, 10, 12.5, and up to 15 mg may occur at 4-week or longer intervals if more glycemic control is needed and the prior dose is tolerated.

Foundayo is titrated starting at a low oral dose and stepped up every 4 weeks to the maintenance or maximum dose depending on response and tolerability. Clinicians may stop at a lower maintenance dose if a patient is responding well.

Side Effect Profiles

Both medications produce the GLP-1 class side-effect pattern: nausea, vomiting, diarrhea, constipation, and dyspepsia, most often mild to moderate and reduced by slow titration.

In the tirzepatide trials, gastrointestinal adverse events were the most common. Tirzepatide may also affect the absorption of oral contraceptives, which is relevant for certain patients.

In ATTAIN-1, the most common adverse events with orforglipron included nausea, diarrhea, vomiting, constipation, dyspepsia, and abdominal pain, with some hair loss and fatigue reported at therapeutic doses.

Both carry a boxed warning regarding thyroid C-cell tumors based on rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both may increase risks of pancreatitis, gallbladder events, and acute kidney injury secondary to dehydration.

Which Drug Fits Which Patient

• A patient with type 2 diabetes seeking an injection with strong glycemic and weight effects may be a candidate for Mounjaro (or, for weight management specifically without diabetes, Zepbound).
• A patient with obesity (or overweight plus a comorbidity) who wants an oral medication without food restrictions may be a candidate for Foundayo.
• A patient who wants oral semaglutide for type 2 diabetes specifically might be considered for Rybelsus rather than either option above.
• For comparisons within the same active ingredient at different labels, see Mounjaro vs Zepbound and Ozempic vs Wegovy.

Cost and Access Notes

Mounjaro has established insurance coverage for type 2 diabetes, though plans vary in their handling of GLP-1 copays. Eli Lilly has published self-pay vial pricing for Zepbound, the tirzepatide obesity label.

Foundayo pricing is being communicated at launch through LillyDirect. Insurance formulary decisions for Foundayo are still evolving and many commercial plans are expected to require prior authorization. Patients should confirm pricing and coverage with their insurer before filling.

This article is for informational purposes only and does not constitute medical advice. Prescribing decisions should be made between a patient and their healthcare provider based on the most current FDA labels and the patient's individual health profile.